Tenet Healthcare Corporation $THC Shares Sold by KBC Group NV

KBC Group NV cut its holdings in shares of Tenet Healthcare Corporation (NYSE:THC) by 5.1% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 50,539 shares of the company’s stock after selling 2,711 shares during the period. KBC Group NV’s holdings in Tenet Healthcare were worth $9,537,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the business. Triumph Capital Management acquired a new stake in Tenet Healthcare in the third quarter valued at approximately $25,000. Activest Wealth Management acquired a new position in shares of Tenet Healthcare during the 4th quarter worth approximately $26,000. Elyxium Wealth LLC purchased a new position in shares of Tenet Healthcare during the 4th quarter valued at approximately $29,000. Canada Pension Plan Investment Board acquired a new stake in Tenet Healthcare in the 2nd quarter valued at $35,000. Finally, Meeder Asset Management Inc. increased its holdings in Tenet Healthcare by 146.2% in the 4th quarter. Meeder Asset Management Inc. now owns 192 shares of the company’s stock worth $38,000 after acquiring an additional 114 shares in the last quarter. Institutional investors and hedge funds own 95.44% of the company’s stock.

Insider Buying and Selling

In other Tenet Healthcare news, Director Nadja West sold 3,000 shares of the firm’s stock in a transaction on Wednesday, May 27th. The stock was sold at an average price of $177.35, for a total value of $532,050.00. Following the completion of the sale, the director directly owned 24,805 shares of the company’s stock, valued at $4,399,166.75. This trade represents a 10.79% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director J Robert Kerrey sold 5,638 shares of the business’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $174.52, for a total transaction of $983,943.76. Following the transaction, the director directly owned 16,804 shares in the company, valued at approximately $2,932,634.08. The trade was a 25.12% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 0.97% of the company’s stock.

Tenet Healthcare Stock Performance

THC opened at $195.84 on Thursday. Tenet Healthcare Corporation has a twelve month low of $146.60 and a twelve month high of $247.21. The firm has a market capitalization of $16.87 billion, a PE ratio of 10.18, a PEG ratio of 1.63 and a beta of 1.27. The company has a current ratio of 1.36, a quick ratio of 1.30 and a debt-to-equity ratio of 1.96. The firm’s 50-day moving average price is $184.41 and its 200 day moving average price is $197.37.

Tenet Healthcare (NYSE:THC) last released its quarterly earnings data on Thursday, April 30th. The company reported $4.82 EPS for the quarter, beating analysts’ consensus estimates of $4.21 by $0.61. The company had revenue of $5.37 billion during the quarter, compared to the consensus estimate of $5.39 billion. Tenet Healthcare had a net margin of 7.94% and a return on equity of 25.55%. Tenet Healthcare’s quarterly revenue was up 2.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $4.36 EPS. Tenet Healthcare has set its FY 2026 guidance at 16.380-18.68 EPS. As a group, sell-side analysts expect that Tenet Healthcare Corporation will post 17.5 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently issued reports on THC shares. TD Cowen dropped their target price on shares of Tenet Healthcare from $242.00 to $233.00 and set a “buy” rating on the stock in a research report on Monday, June 22nd. Morgan Stanley set a $254.00 price target on shares of Tenet Healthcare in a research note on Friday, May 1st. Stephens lowered their price objective on Tenet Healthcare from $275.00 to $260.00 and set an “overweight” rating on the stock in a report on Monday, May 4th. Guggenheim reduced their target price on Tenet Healthcare from $252.00 to $242.00 and set a “buy” rating for the company in a report on Monday. Finally, Robert W. Baird lowered their price target on Tenet Healthcare from $245.00 to $210.00 and set a “neutral” rating on the stock in a research note on Tuesday, May 5th. Seventeen investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $244.84.

Tenet Healthcare Company Profile

Tenet Healthcare Corporation (NYSE: THC) is a diversified American healthcare services company that owns and operates acute care hospitals and a broad range of outpatient facilities. Its portfolio includes general acute-care hospitals, specialty hospitals, ambulatory surgery centers, urgent care and diagnostic imaging centers, and other ancillary service locations. Tenet’s operations are oriented around delivering inpatient and outpatient clinical care across multiple medical specialties, with an emphasis on surgical services, emergency care, and advanced diagnostics.

In addition to facility-based care, Tenet provides integrated services designed to support clinical operations and improve patient access and care coordination.